Release date: January 17, 2022
Expiration date: January 17, 2024
Estimated Time of Completion: 30 minutes
Description
The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.
Learning Objectives
- Summarize recent treatment advances in paroxysmal nocturnal hemoglobinuria and describe how complement inhibitors fit into management strategies.
Target Audience
The virtual satellite symposium is designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS, AML and myeloid malignancies. In addition, members of patient advocacy groups will benefit from this program.
Accreditation
In support of improving patient care, this activity has been planned and implemented by Cleveland Clinic Center for Continuing Education and Aplastic Anemia & MDS International Foundation. Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Medical Association (AMA)
Cleveland Clinic Foundation Center for Continuing Education designates this internet enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
American Nurses Credentialing Center (ANCC)
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 0.5 ANCC contact hours.
American Academy of PAs (AAPA)
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Certificate of Participation
A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations
Activity Director and Faculty
Activity Director
Bhumika Patel, MD
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
Sudipto Mukherjee, MD, PhD, MPH
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
Faculty
Antonio Risitano, MD, PhD
Head of the Clinical Unit of Hematopoietic Stem Cell Transplantation, Hematology, Department of Biochemistry and Medical Biotechnologies
University of Naples
Naples, Italy
CME Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.
Disclosures
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty member has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
Sudipto Mukherjee, MD |
Aplastic Anemia and MDS International Foundation |
Honorarium - Activity Director of ASH Friday Satellite Symposium 2020 |
Eusa Pharma |
Consulting Advisor or review panel participant Teaching and Speaking |
Novartis |
Consulting Research / Independent Contractor Advisor or review panel participant |
McGraw Hill |
Honoraria - Editor of Hematology Oncology Board Review (ongoing) |
Bristol-Myers Squibb Co. |
Advisor or review panel participant Honoraria |
Celgene Corporation |
Board Membership Consulting Research / Independent Contractor Advisor or review panel participant Research Funding - non-therapeutic investigator trials. Formerly Celgene (now BMS) |
Antonio Risitano, MD |
Alexion |
Board Membership Teaching and Speaking |
Apellis Pharmaceuticals |
Board Membership Teaching and Speaking |
Novartis |
Board Membership Consulting Research / Independent Contracto Teaching and Speaking |
Pfizer |
Board Membership Research / Independent Contractor Teaching and Speaking |
BioCryst Pharmaceuticals, Inc. |
Board Membership Consulting |
Roche |
Board Membership Consulting |
Acknowledgement
The Aplastic Anemia and MDS International Foundation and Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this internet enduring activity from:
Alexion Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.
Ascentage Pharma Group, Inc.
Biocryst Pharmaceuticals Inc.
Bristol-Myers Squibb
Geron Corporation
Taiho Oncology
Takeda Oncology
|
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.